June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Is Dark Chocolate (Resveratrol) neuroprotective in a model of Alzheimer’s disease?
Author Affiliations & Notes
  • Ehtesham Shamsher
    Institute of Ophthalmology, University College London, London, London, United Kingdom
    Jules-Gonin Eye Hospital, Universite de Lausanne, Lausanne, Vaud, Switzerland
  • Li Guo
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Benjamin Davis
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Vy Luong
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Nivedita Ravindran
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Satyanarayana Somavarapu
    School of Pharmacy, University College London, London, London, United Kingdom
  • M Francesca Cordeiro
    Institute of Ophthalmology, University College London, London, London, United Kingdom
    Ophthalmology Research Group, Imperial College London, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Ehtesham Shamsher None; Li Guo None; Benjamin Davis UCLB, Code P (Patent); Vy Luong None; Nivedita Ravindran None; Satyanarayana Somavarapu UCLB, Code P (Patent); M Francesca Cordeiro UCLB, Code P (Patent)
  • Footnotes
    Support  Swiss Study Foundation Scholarship; Janggen-Pöhn Foundation Scholarship, University College London Overseas Research Scholarship
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4139 – F0376. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ehtesham Shamsher, Li Guo, Benjamin Davis, Vy Luong, Nivedita Ravindran, Satyanarayana Somavarapu, M Francesca Cordeiro; Is Dark Chocolate (Resveratrol) neuroprotective in a model of Alzheimer’s disease?. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4139 – F0376.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Alzheimer’s disease (AD) is the major cause of dementia in the world with increasing evidences of the retina being affected. Since no cure exists, there is an urgent unmet need to find new treatments. Resveratrol, a natural polyphenol found in dark chocolate and red wine, has been advocated as a potential neuroprotectant in this disease. However, resveratrol has a low solubility and bioavailability limiting its clinical translation. In this study, we assessed a novel formulation of resveratrol in vitro and in vivo in a triple transgenic Alzheimer’s disease (3xTg-AD) mouse model.

Methods : Resveratrol nanoparticles (RNs) were formulated using a thin rehydration technique. They were assessed in vitro on R28 cells against glutamate excitotoxicity and cobalt chloride induced hypoxia. Next, 3xTg-AD mice received intranasally either RNs (n=7) or an equivalent vehicle (n=6) 5 days a week for 3 months. After 3 months of treatment, animals were imaged using Detection of Apoptosing Retinal Cells (DARC). DARC count was defined as the number of fluorescent spots counted by a masked investigator. After sacrifice, their brains were harvested and immunostained for amyloid-beta (Aβ) and phosphorylated tau (pTau). Retinas were immunostained with Brn3a, a retinal ganglion cell (RGC) marker.

Results : RN formulation incorporating over 10 mg/ml resveratrol was stable over 90 days. RNs were able to protect R28 cells exposed to glutamate compared to the vehicle (IC50 25.1±0.4 vs 14.4±1.0 mM, p<0.0001) but did not show any neuroprotection against cobalt chloride induced hypoxia compared to the vehicle (260.3±16.5 vs 200.7±22.3 µM, p>0.05). In vivo, DARC count was reduced with RN treatment compared to the vehicle (7.7±2.1 vs 49.1±13.3, p<0.01). However, these results did not correlate with a higher RGC density compared to the vehicle (1205±203 vs 1015±100 cells/mm2, p>0.05). Interestingly, Aβ and pTau depositions in the brain were reduced with RN treatment compared to the vehicle (3.6±0.2 vs 4.5±0.2 Aβ score, p<0.01 and 2.1±0.5 vs 6.6±1.9 pTau score, p<0.05). No adverse effects were seen in vivo either systemically or in the eye.

Conclusions : These promising results show that RN is non-toxic and neuroprotective in vitro and in vivo when administered intranasally. However, DARC imaging failed to show a correlation with RGC density. Further studies are needed to confirm these results.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×